Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation?...Cytochrome P450 2C9

Background: We previously reported on a Swedish patient with Behçet's disease (BD) who was an ultra-rapid metaboliser of drugs catalysed by CYP2C9. Was this extreme metabolism caused by the disease? Aim: This study aims to compare the genotype/phenotype of CYP2C9 in patients with BD and healthy subj...

Full description

Bibliographic Details
Published in:European Journal of Clinical Pharmacology Vol. 71; no. 10; pp. 1223 - 1229
Main Authors: Goktaş, Mustafa, Hatta, Fazleen, Karaca, Ozgur, Kalkisim, Said, Kilic, Levent, Akdogan, Ali, Babaoglu, Melih, Bozkurt, Atilla, Helldén, Anders, Bertilsson, Leif, Yasar, Umit
Format: research tables/charts Journal Article
Published: Springer Nature Oct2015
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109345398&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 109345398
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Oct2015
      vid: 71
      iid: 10
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        109345398
        109345398
        109345398
        10.1007/s00228-015-1899-7
        109345398
      ppf: 1223
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation?...Cytochrome P450 2C9
      aug:
        au:
          Goktaş, Mustafa
          Hatta, Fazleen
          Karaca, Ozgur
          Kalkisim, Said
          Kilic, Levent
          Akdogan, Ali
          Babaoglu, Melih
          Bozkurt, Atilla
          Helldén, Anders
          Bertilsson, Leif
          Yasar, Umit
        affil: Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara Turkey
      sug:
        subj:
          Oxidoreductases Analysis
          Behcet's Syndrome Physiopathology
          Inflammation
          Genotype
          Phenotype
          Behcet's Syndrome Complications
          Human
          Turkiye
          Polymerase Chain Reaction
          Losartan Administration and Dosage
          Descriptive Statistics
          T-Tests
          Colchicine Therapeutic Use
          Behcet's Syndrome Drug Therapy
          Cytokines
          Losartan Metabolism
          Fisher's Exact Test
          Chi Square Test
          Data Analysis Software
          Male
          Female
          Adult
          Middle Age
          Aged
          Polymorphism, Genetic
          Confidence Intervals
          Funding Source
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Background: We previously reported on a Swedish patient with Behçet's disease (BD) who was an ultra-rapid metaboliser of drugs catalysed by CYP2C9. Was this extreme metabolism caused by the disease? Aim: This study aims to compare the genotype/phenotype of CYP2C9 in patients with BD and healthy subjects. As the occurrence of BD is high in Turkey, all subjects were recruited from this country. Methods: Genotyping of CYP2C9 was performed using standard PCR-RFLP and allele-specific PCR methods. Phenotyping of CYP2C9 was performed by administration of a 50-mg single oral dose of losartan and by calculating the urinary metabolic ratio (MR) of probe drug to its metabolite E-3174. Quantitation was performed by HPLC. Results: The frequency of CYP2C9*2 and *3 was not significantly different between the Behçet's disease patients (12.5 and 8.7 %) and the healthy subjects (8.9 and 8.2 %). The geometric mean losartan MR was higher in the 52 patients (1.75) than in the 96 healthy subjects (1.02) ( p = 0.002; t-test). Within the genotypes *1/*1, there was a significant difference of MR between patients and healthy subjects ( P = 0.006). All but three of the Behçet's disease patients were treated with colchicine. In nine subsequent patients, we found no significant effect of 2 weeks of treatment with colchicine on the CYP2C9 MR. Conclusion: Contrary to expectation, the CYP2C9 activity was lower in Turkish BD patients compared to healthy subjects. As this seems not to be due to colchicine treatment, our hypothesis is that inflammation related to BD might have caused the down-regulation of the CYP2C9 activity due to immune cytokine reactions. The ultra-rapid metabolism of CYP2C9 substrate drugs in the Swedish patient was not due to her BD.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N